Jiangsu Hengrui Medicine (600276.SS) Earnings
Price: $48.61
Market Cap: $308.64B
Market Cap: $308.64B
Revenue (TTM): $22.82B
Net Income: $4.30B
Net Income: $4.30B
P/E Ratio: 56.65
EPS (TTM): $0.86
EPS (TTM): $0.86
Earnings Dates
Jiangsu Hengrui Medicine (600276.SS) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: March 31, 2025
- Time of Day: Before Market Open
- Estimated EPS: $0.35
Last Earnings Report
- Date: October 24, 2024
- EPS: $0.19
- EPS Estimate: $0.23
Jiangsu Hengrui Medicine 's next earnings report is scheduled for March 31, 2025.
In its last earnings report on October 24, 2024, Jiangsu Hengrui Medicine reported earnings per share (EPS) of $0.19, compared to an estimated EPS of $0.23. The company reported revenue of $6.59B, compared to an estimated revenue of $933.55M.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| October 24, 2024 | $0.19 | $0.23 | $6.59B | $933.55M |
| August 21, 2024 | $0.33 | $0.33 | $7.55B | $1.01B |
| April 26, 2024 | $0.21 | $0.20 | $6.00B | $6.25B |
| April 17, 2024 | $0.14 | $0.17 | $5.81B | $831.78M |
| October 25, 2023 | $0.18 | $0.21 | $5.85B | $6.23B |
| August 18, 2023 | $0.17 | $0.18 | $5.68B | $6.70B |
| May 30, 2023 | $0.19 | $0.19 | $5.49B | $5.59B |
| April 21, 2023 | $0.19 | $0.19 | $5.33B | $5.59B |
| October 28, 2022 | $0.17 | $0.18 | $5.72B | $5.92B |
| August 19, 2022 | $0.14 | $0.20 | $4.75B | $5.22B |
| April 22, 2022 | $0.05 | $0.30 | $5.71B | $7.17B |
| March 30, 2022 | $0.19 | $ | $5.48B | $- |
| October 19, 2021 | $0.24 | $0.30 | $6.90B | $8.63B |
| August 19, 2021 | $0.19 | $0.27 | $6.37B | $- |
| April 20, 2021 | $0.23 | $0.21 | $8.32B | $- |
| March 30, 2021 | $0.23 | $ | $6.93B | $- |
Annual Earnings
Annual Revenue
$22.82B
Fiscal Year 2023Annual Net Income
$4.30B
Fiscal Year 2023Annual EPS
$0.68
Fiscal Year 2023Quarterly Earnings
Revenue
$6.59B
Quarter Ending September 30, 2024Net Income
$1.19B
Quarter Ending September 30, 2024EPS
$0.19
Quarter Ending September 30, 2024Earnings Metrics
Earnings Yield
1.50%
Year Ending December 31, 2023P/E Ratio
66.51
Year Ending December 31, 2023Revenue Per Share
$3.61
Year Ending December 31, 2023Earnings Yield (TTM)
1.77%
Trailing Twelve MonthsP/E Ratio (TTM)
56.65
Trailing Twelve MonthsRevenue Per Share (TTM)
$4.09
Trailing Twelve MonthsFrequently Asked Questions
Jiangsu Hengrui Medicine 's next earnings date is scheduled for March 31, 2025. The earnings call is expected to take place before market open.
In its last earnings report on October 24, 2024, Jiangsu Hengrui Medicine reported earnings per share (EPS) of $0.19, compared to an estimated EPS of $0.23. The company reported revenue of $6.59B, compared to an estimated revenue of $933.55M.
Jiangsu Hengrui Medicine 's current Price-to-Earnings (P/E) ratio is 66.51. The trailing twelve months (TTM) P/E ratio is 56.65. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2023, Jiangsu Hengrui Medicine reported total revenue of $22.82B and net income of $4.30B. This represents a net profit margin of 0.1885397246.
Jiangsu Hengrui Medicine 's earnings yield is 1.50%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Jiangsu Hengrui Medicine 's return on equity (ROE) is 10.63%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Jiangsu Hengrui Medicine 's gross profit margin is 84.55%. This indicates that for every dollar of revenue, the company retains $0.85 as gross profit after accounting for the cost of goods sold.
Related Metrics
Explore detailed financial metrics and analysis for 600276.SS.